EUCTR2005-005238-11-FR进行中（未招募）1 期
Belatacept Conversion Trial in Renal Transplantation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) The subject is willing to provide signed written informed consent
- •2) Subjects must be a recipient of a renal allograft from a living donor or a deceased donor at least 6 months, but not longer than 36 months, prior to randomization
- •3) Subjects must be receiving a CNI-based (CsA [any formulation] or TAC) immunosuppressive regimen
- •4) The dose of CNI must have been stable over the month prior to randomization
- •a) For subjects receiving CsA, trough serum concentration at the time of enrollment must be 100-250 ng/mL (based on screening/baseline central laboratory results)
- •b) For subjects receiving TAC, trough serum concentration at the time of enrollment must be 5-10 ng/mL (based on screening/baseline central laboratory results)
- •5) Subjects must be receiving adjunctive background maintenance immunosuppression with MMF, MPA, SRL, or AZA
- •a) Subjects receiving MMF must have received a minimum total daily dose of 1.5 g for the month prior to randomization (up to 3 missed doses are acceptable provided doses were not missed due to drug intolerance)
- •b) Subjects receiving MPA must have received a minimum total daily dose of 1080 mg for the month prior to randomization (up to 3 missed doses are acceptable provided doses were not missed due to drug intolerance)
- •c) Subjects receiving AZA must have received a minimum daily dose of 50 mg for the month prior to randomization (up to 3 missed doses are acceptable provided doses were not missed due to drug intolerance)
- •d) Subjects receiving SRL must have a trough serum concentration at the time of enrollment of 5-15 ng/mL (based on screening/baseline central laboratory results)
- •6) If subjects are receiving concomitant corticosteroids (steroid use is not required), the dose of corticosteroid must have been stable over the month prior to randomization with no anticipated dose alteration in the next 6 months
- •7) Subjects must have a calculated GFR = 35 and = 75 mL/min/1.73 m2 (MDRD formula) at the time of enrollment (based on screening/baseline central laboratory results)
- •8) Men and women, ages 18 years and older, inclusive
- •9) WOCBP must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the study in such a manner that the risk of pregnancy is minimized.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last infusion of study medication
- •2) WOCBP using a prohibited contraceptive method
- •3) Women who are pregnant or breastfeeding
- •4) Women with a positive pregnancy test on enrollment or prior to study drug
- •administration
- •5) Subjects with underlying renal disease of:
- •a) Primary focal segmental glomerulosclerosis
- •b) Type I or II membranoproliferative glomerulonephritis
- •c) Hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenic purpura syndrome
- •6) Subjects expected to undergo weaning of immunosuppressive therapy during the period of the study
- •7) Subjects with a pre-transplant panel reactive antibodies (PRA) = 50%
- •8) Subjects with previous graft loss due to acute rejection (AR)
- •9) Subjects whose SCr at enrollment is over 30% higher than 3 months (± 4 weeks) prior to randomization
- •10) Subjects with an episode of AR in the last 3 months. Subjects who have had an episode of AR are required to have had clinical resolution for at least 3 months prior to randomization
- •11) Subjects who have had a Banff 97 Grade IIA or greater AR (or equivalent), steroid-resistant AR or have received lymphocyte-depleting agents, plasmapheresis, or rituximab for the treatment of AR since transplantation of current allograft
- •12) Subjects who have experienced more than 1 episode of rejection of the current allograft
- •13) Subjects with a biopsy of the current allograft staining C4d positive. Neither a biopsy nor C4d staining is required for entry into the study
- •14) Subjects who have experienced complications of anastomotic stenosis or stricture (vascular or ureteral)
- •15) Subjects who had a positive T-cell or B-cell crossmatch
- •16) Subjects who have documented BK virus (polyoma virus) nephropathy (biopsy is not required for enrollment)
- •17) Subjects who have documented evidence of recurrence of the primary cause of end-stage renal disease (ESRD) in their current or in a past renal allograft
- •18) Subjects with multiple solid organ (heart, liver, pancreas) or cell (islet, bone marrow, stem cell) transplants
- •19) Subjects who received paired kidneys (dual or en bloc kidney transplants)
- •20) Subjects who are known hepatitis C antibody-positive or PCR-positive for hepatitis C (neither hepatitis C antibody or PCR for hepatitis C testing is required for entry into the study)
- •21) Subjects who are known hepatitis B surface antigen-positive or PCR-positive for
- •hepatitis B (neither hepatitis B surface antigen or PCR for hepatitis B testing is required for entry into the study)
- •22) Subjects with known HIV infection. HIV testing is not required for entry into the study
- •23) Subjects with a chest radiograph (posterior-anterior and lateral views) consistent with an acute lung parenchymal process, malignancy, or active tuberculosis. Subjects must have a chest radiograph within 2 months prior to randomization
- •24) Subjects with any significant infection
- •Medical History and Concurrent Diseases
- •25) Subjects whose life expectancy is severely limited by disease state or other underlying medical condition
- •26) Subjects with a history of cancer (other than non-melanoma skin cell cancers cured by local resection) within the last 5 years
- •27) Subjects with a history of substance abuse (drug or alcohol) within the past 5 years, or psychotic disorders that are not compatible with adequate study follow-up
- •Physical and Laboratory Test Findings
- •28) Subjects with l
研究者
相似试验
进行中（未招募）
不适用
Belatacept Conversion Trial in Renal TransplantationRevised Protocol 02 incorporating Amendments 03 (version 1.0 dated 18-Sep-07) and 04 (version 3.0 dated 12-Oct-07)Subjects who received a kidney transplantEUCTR2005-005238-11-DEBristol-Myers Squibb International Corporation170
进行中（未招募）
1 期
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine orTacrolimus Regimen With or Without CorticosteroidsSubjects who received a kidney transplantEUCTR2005-005238-11-BEBristol-Myers Squibb International Corporation170
已完成
2 期
A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without CorticosteroidsRenal TransplantNCT00402168Bristol-Myers Squibb173
招募中
4 期
Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>Kidney DiseasesNCT06291077University Hospital, Rouen44
Unknown
不适用
Metabolic and Infectious Complications Post Belatacept ConversionKidney Transplant InfectionCardiovascular DiseasesImmunosuppressionKidney Transplant ComplicationsNCT05316038University Hospital, Grenoble100